Taisho Pharmaceutical Holdings Co., Ltd.
4581
株式のランク
#3722
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
株価
$54.31
最終同期: 2024-04-08
時価総額
$4.45B
変化（1日）
-4.14%
変化（1年）
0.00%
国
JP
取引 Taisho Pharmaceutical Holdings Co., Ltd. (4581)
カテゴリー
Healthcare
Taisho Pharmaceutical Holdings Co., Ltd.（4581）の発行済株式数
October 2026 時点の発行済株式数 0
Taisho Pharmaceutical Holdings Co., Ltd. の最新の財務報告および株価によると、現在の発行済株式数は 0 です。October 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Taisho Pharmaceutical Holdings Co., Ltd.（4581）の発行済株式数の履歴（2006 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2023 | 81.98M | 0.66% |
| 2022 | 81.44M | 2.04% |
| 2021 | 79.82M | 0.00% |
| 2020 | 79.82M | 0.00% |
| 2019 | 79.82M | -0.09% |
| 2018 | 79.89M | -0.02% |
| 2017 | 79.91M | -1.24% |
| 2016 | 80.91M | -0.19% |
| 2015 | 81.07M | -0.02% |
| 2014 | 81.09M | 0.21% |
| 2013 | 80.92M | -1.60% |
| 2012 | 82.23M | -1.88% |
| 2011 | 83.81M | -2.54% |
| 2010 | 85.99M | -2.41% |
| 2009 | 88.12M | -1.32% |
| 2008 | 89.29M | -2.51% |
| 2007 | 91.60M | -0.95% |
| 2006 | 92.47M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | - |
IN
|
